Structural basis of a shared antibody response to SARS-CoV-2
Open accessPublished version of a preprint
The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Molecular understanding of neutralizing antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could accelerate vaccine design and drug discovery. We analyzed 294 anti-SARS-CoV-2 antibodies and found that immunoglobulin G heavy-chain variable region 3-53 (IGHV3-53) is the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein. Co-crystal structures of two IGHV3-53-neutralizing antibodies with RBD, with or without Fab CR3022, at 2.33- to 3.20-angstrom resolution revealed that the germline-encoded residues dominate recognition of the angiotensin I converting enzyme 2 (ACE2)-binding site. This binding mode limits the IGHV3-53 antibodies to short complementarity-determining region H3 loops but accommodates light-chain diversity. These IGHV3-53 antibodies show minimal affinity maturation and high potency, which is promising for vaccine design. Knowledge of these structural motifs and binding mode should facilitate the design of antigens that elicit this type of neutralizing response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of public antibody responses have been reported for SARS-CoV-2, principal among these being VH3–53/VH3–66 and VH1–58 (VH3–30 is also found, but the antibodies are not potent neutralizers) (Yuan et al., 2020; Barnes et al., 2020; Dejnirattisai et al., 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Their engagement with the RBD is dictated by CDR-H1 and CDR-H2, while the CDR-H3 is characteristically short and makes rather few interactions”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Yuan et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
NMRPipe: A multidimensional spectral processing system based on UNIX pipes
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., & Bax, A. (1995) · Journal of Biomolecular NMR · doi:10.1007/bf00197809 · Cited by 15,965
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983
Cited by
Items 301–400 of 597
Yang, X., Chi, H., Wu, M., Wang, Z., Lang, Q., Han, Q., Wang, X., Liu, X., Li, Y., Wang, X., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.992787 · Cited by 20
“On the one hand, this is probably due to the fact that SARS-CoV-2 neutralizing antibodies isolated from human are frequently encoded by convergent heavy-chain variable genes that share similar binding modes and footprints (10, 11).”
BackgroundMolecular features of IGHV3-53-encoded antibodies elicited by SARS-CoV-2
Fagiani, F., Catanzaro, M., & Lanni, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00287-4 · Cited by 18
“3 to SARS-CoV-2 RBD of 17 and 14 nM, respectively.(1,4) By performing competitions experiments, Yuan et al.”
BackgroundMethodMakdasi, E., Zvi, A., Alcalay, R., Noy-Porat, T., Peretz, E., Mechaly, A., Levy, Y., Epstein, E., Chitlaru, T., Tennenhouse, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109679 · Cited by 23
Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago
Qiang, M., Ma, P., Li, Y., Liu, H., Harding, A. C., Min, C., Wang, F., Liu, L., Yuan, M., Ji, Q., et al. (2021) · Advanced Science · doi:10.1002/advs.202102181 · Cited by 21
Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike ProteinsPreprint
Wang, Z.-J., Muecksch, F., Cho, A., Gaebler, C., Hoffmann, H., Ramos, V. A., Zong, S., Cipolla, M., Johnson, B., Schmidt, F., et al. (2022) · bioRxiv · doi:10.1101/2022.02.01.478695 · Cited by 20
“…the neutralizing antibodies to RBD showed that infected or vaccinated humans produce a convergent set of neutralizing antibodies dominated by specific Ig heavy chain variable (IGVH) regions (Barnes et al., 2020b; Brouwer et al., 2020; Robbiani et al., 2020; Wang et al., 2021d; Yuan et al., 2020).”
BackgroundLuo, M., Zhou, R., Tang, B., Liu, H., Chen, B., Liu, N., Mo, Y., Zhang, P., Lee, Y. L., Ip, J. D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105354 · Cited by 18
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062928 · Cited by 17
Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
Liu, C., Das, R., Dijokaite-Guraliuc, A., Zhou, D., Mentzer, A. J., Supasa, P., Selvaraj, M., Duyvesteyn, H. M. E., Ritter, T. G., Temperton, N. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47393-3 · Cited by 17
“mAbsbind onornearthereceptorbindingmotif 5 ,a small25aminoacid patch at the tip of the RBD. mAbs binding here neutralize by blocking the binding of S to the SARS-CoV-2 cellular receptor angiotensin-converting enzyme 2 (ACE-2) 10 .”
Chen, J., Li, S., Lei, Z., Tang, Q., Mo, L., Zhao, X., Xie, F., Zi, D., & Tan, J. H. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.61476 · Cited by 19
“Previous studies have identified residues located in N-terminal helix of ACE2 receptors is critical for binding to S-protein of SARS-CoV or SARS-CoV-2 [31-33].”
Backgroundde Mattos Barbosa, M. G., Liu, H., Huynh, D., Shelley, G., Keller, E. T., Emmer, B. T., Sherman, E., Ginsburg, D., Kennedy, A. A., Tai, A. W., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.147386 · Cited by 14
“These Abs had few somatic mutations, and Yuan et al. (26) found that recognition of ACE2 by the RBD was mediated by germline-encoded residues (NY motif at VH residues 32 and 33 in the CDRH1 and an SGGS motif at VH residues 53 to 56 in CDRH2), suggesting that neutralization potency was dissociated…”
InfluentialSelf-citationDevelopment of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
Seydoux, E., Wan, Y.-H., Feng, J., Wall, A., Aljedani, S., Homad, L. J., MacCamy, A. J., Weidle, C., Gray, M. D., Brumage, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109084 · Cited by 16
“…non-HIV B cell targets with well-defined genetic features could be generated, such as those that target unmutated VH3–53-derived B cells, which recognize the receptor-binding domain of SARS-CoV-2 and potently neutralize the virus (Barnes et al., 2020; Yuan et al., 2020; Hurlburt et al., 2020).”
Analysis of the molecular mechanism of SARS-CoV-2 antibodies
Jin, D., Wei, J., & Sun, J. (2021) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2021.06.001 · Cited by 16
Teng, Y. H. F., Quah, H. S., Suteja, L., Dias, J. M. L., Mupo, A., Bashford-Rogers, R. J. M., Vassiliou, G. S., Chua, M. L. K., Tan, D. S. W., Lim, W., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03047-7 · Cited by 20
Wang, D., Ge, Y., Zhong, B., & Liu, D. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.03.021 · Cited by 15
“Considering that VL S93 is also conserved in some IGHV3-53 encoded antibodies [29], VL S93 may also be another important residue in CDR L for this type of antibodies.”
InfluentialSARS-CoV-2 receptor-binding mutations and antibody contact sites
Mejdani, M., Haddadi, K., Pham, C., & Mahadevan, R. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab015 · Cited by 18
Nie, J., Xie, J., Liu, S., Wu, J., Liu, C., Li, J., Liu, Y., Wang, M., Zhao, H., Zhang, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00292-z · Cited by 15
Ozawa, T., Tani, H., Anraku, Y., Kita, S., Igarashi, E., Saga, Y., Inasaki, N., Kawasuji, H., Yamada, H., Sasaki, S., et al. (2022) · mAbs · doi:10.1080/19420862.2022.2072455 · Cited by 18
“Neutralizing antibodies often utilize public variable region genes, such as IGHV3-53, IGHV3-66, IGHV3-30, IGHV1-2, and IGHV1-69.(8,30,31) We therefore analyzed the antibody variable gene repertoires.”
BackgroundFrequent use of IGHV3-30-3 in SARS-CoV-2 neutralizing antibody responses
Pushparaj, P., Nicoletto, A., Dopico, X. C., Sheward, D. J., Kim, S., Ekström, S., Murrell, B., Corcoran, M., & Hedestam, G. B. K. (2023) · Frontiers in Virology · doi:10.3389/fviro.2023.1128253 · Cited by 16
“Studies have shown that germline-encoded amino acid motifs in IGHV3-53 make direct contacts with the RBD, explaining the potency of this class of antibodies despite low levels of somatic hypermutation (SHM) (3, 19, 20).”
BackgroundInfluentialChen, E. C., Gilchuk, P., Zost, S. J., Ilinykh, P. A., Binshtein, E., Huang, K., Myers, L., Bonissone, S. R., Day, S., Kona, C. R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112370 · Cited by 18
“20,32 Groups 2.23 and 2.22 are encoded by IGHV1–69 and IGHV1–02, both commonly used heavy variable genes encoding public clonotypes that recognize diverse viral pathogens.”
BackgroundInfluentialA hijack mechanism of Indian SARS-CoV-2 isolates for relapsing contemporary antiviral therapeutics
Prathiviraj, R., Saranya, S. V., Bharathi, M., & Chellapandi, P. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104315 · Cited by 15
Engelhart, E., Lopez, R. M., Emerson, R., Lin, C., Shikany, C., Guion, D., Kelley, M., & Younger, D. A. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac011 · Cited by 18
Recent advances in detection technologies for COVID-19
Han, T., Cong, H., Shen, Y., & Yu, B. (2021) · Talanta · doi:10.1016/j.talanta.2021.122609 · Cited by 18
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00124 · Cited by 18
Neutralizing and enhancing antibodies against SARS-CoV-2
Liu, Y., & Arase, H. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00233-7 · Cited by 14
Changrob, S., Halfmann, P., Liu, H., Torres, J. L., McGrath, J. J. C., Ozorowski, G., Li, L., Wilbanks, G. D., Kuroda, M., Maemura, T., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166844 · Cited by 13
“3, B38, and C105 (13, 18, 23, 29, 38, 39), tend to use IGHV3-53 or 3-66 and are sensitive to VOC mutations (40).”
Su, H., Zhang, J., Yi, Z., Khan, S. U., Peng, M., Ye, L., Bao, A., Zhang, H., Suo, G., Li, Q., et al. (2024) · hLife · doi:10.1016/j.hlife.2024.02.001 · Cited by 15
Paciello, I., Pierleoni, G., Pantano, E., Antonelli, G., Pileri, P., Maccari, G., Cardamone, D., Realini, G., Perrone, F., Neto, M. M., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114645 · Cited by 19
Yan, Q., Gao, X., Liu, B., Hou, R., He, P., Ma, Y., Zhang, Y., Zhang, Y., Li, Z., Chen, Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51770-3 · Cited by 16
“K417N is located in the epitope of VH3-53/3-66 encoded class 1 antibodies inhibiting ACE2 binding 13 – 15 ; L452R is located in the epitope of VH1-69 encoded population antibodies 16 – 18 ; E484A islocated in the epitope of VH1-2 encoded class2populationantibodies 19 – 21 .”
BackgroundKuwata, T., Kaku, Y., Biswas, S., Matsumoto, K., Shimizu, M., Kawanami, Y., Uraki, R., Okazaki, K., Minami, R., Nagasaki, Y., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105439 · Cited by 13
The development of neutralizing antibodies against SARS-CoV-2 and their common features
Liu, L. D., Lian, C., Yeap, L.-S., & Meng, F. (2020) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaa070 · Cited by 14
Qiang, X., Zhu, S., Li, J., Chen, W., Yang, H., Wang, P., Tracey, K. J., & Wang, H. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.3covcra0920-628rr · Cited by 13
Zhao, F., Keating, C., Ozorowski, G., Shaabani, N., Francino-Urdaniz, I. M., Barman, S., Limbo, O., Burns, A., Zhou, P.-P., Ricciardi, M. J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104914 · Cited by 14
SARS-CoV-2 variants resist antibody neutralization and broaden host ACE2 usagePreprint
Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.09.434497 · Cited by 14
“They are not only 97 rapidly displacing local SARS-CoV-2 strains, but also carry RBD mutations that are 98 critical for interactions with the ACE2 receptor and neutralizing antibodies (35-38).”
BackgroundMemory B cells anticipate SARS-CoV-2 variants through somatic hypermutation
Bruhn, M., Obara, M., Chiyyeadu, A., Costa, B., Salam, M. A., Ziegler, A., Waltl, I., Pavlou, A., Bonifacius, A., Hoffmann, M., et al. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.10.020 · Cited by 14
Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2
Wang, Q., Guo, Y., Casner, R. G., Yu, J., Nair, M. S., Ho, J., Reddem, E. R., Mellis, I. A., Wu, M., Tzang, C.-C., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-61472-z · Cited by 15
“The Fab waspredominantly bound to the spike proteinin a three-RBD-up conformation, like other VH3-53/66 class antibodies targeting the class1 region 39 .”
Germinal center–mediated broadening of B cell responses to SARS-CoV-2 booster immunization
Malladi, S. K., Jaiswal, D., Ying, B., Alsoussi, W. B., Darling, T. L., Dadonaite, B., Civljak, A., Horvath, S. C., Zhou, J. Q., Kim, W., et al. (2025) · Science Immunology · doi:10.1126/sciimmunol.adu4107 · Cited by 15
Chia, W. N., Tan, C. W., Tan, A. W. K., Young, B. E., Starr, T. N., López, E., Fibriansah, G., Barr, J. A., Cheng, S. M. S., Yeoh, A. Y.-Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade3470 · Cited by 17
“We then performed functional characterizations on three of the most potent mAbs (E7, F1, and F5) and benchmarked them against the five control mAbs (S309, CR3022, S2X259, S2K146, and LyCoV1404).”
BackgroundInfluentialAn ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation
Park, S., Choi, J., Lee, Y., Noh, J., Kim, N., Lee, J., Cho, G., Kim, S., Yoo, D. K., Kang, C. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47743-1 · Cited by 15
“2a), in which CDR1 and CDR2 are known to have two key motifs providing reactivity to ancestral RBD 23,29 .”
Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19
Chen, J., Huang, R., Nie, Y., Wen, X., & Wu, Y. (2020) · Virologica Sinica · doi:10.1007/s12250-020-00327-x · Cited by 12
“S309 can neutralize both SARS-CoV and SARS-CoV-2, while CR3022, CR3014, 80R, and m396 can only neutralize SARS-CoV.”
BackgroundResultInfluentialXu, H., Wang, B., Zhao, T.-N., Liang, Z., Peng, T., Song, X., Wu, J., Wang, Y., & Su, X. (2021) · Cell Research · doi:10.1038/s41422-021-00554-1 · Cited by 13
Kim, J., Lee, S. K., Lee, J., Kim, H., Kim, N. H., Lee, C. H., Lee, C., & Kim, H. G. (2022) · Advanced Materials Interfaces · doi:10.1002/admi.202102046 · Cited by 13
mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 and BA.5
Andreano, E., Paciello, I., Pierleoni, G., Maccari, G., Antonelli, G., Abbiento, V., Pileri, P., Benincasa, L., Giglioli, G., Piccini, G., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37422-y · Cited by 15
Delineating antibody escape from Omicron sublineagesPreprint
Gruell, H., Vanshylla, K., Korenkov, M., Tober-Lau, P., Zehner, M., Münn, F., Janicki, H., Augustin, M., Schommers, P., Sander, L., et al. (2022) · bioRxiv · doi:10.1101/2022.04.06.487257 · Cited by 11
enclone: precision clonotyping and analysis of immune receptorsPreprint
Jaffe, D. B., Shahi, P., Adams, B. A., Chrisman, A. M., Finnegan, P., Raman, N., Royall, A. E., Tsai, F., Vollbrecht, T., Reyes, D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.21.489084 · Cited by 14
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 12
“Importantly, the antibody response to RBD appears to be dominated by near-germline sequences coded by the VH3-53 gene, binding conserved residues such as K417 and E484 (Wu et al., 2020a; Yuan et al., 2020), which represent a pool of shared antibody responses among individuals.”
BackgroundBiophysical Fitness Landscape of the SARS-CoV-2 Delta Variant Receptor Binding Domain
Patrick, C., Upadhyay, V., Lucas, A., & Mallela, K. M. G. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167622 · Cited by 14
“1.(54,55) As of January 2022, FDA approved four therapeutic antibodies for emergency use authorization (EUA): Eli Lilly’s LY-CoV016”
BackgroundRadić, L., Sliepen, K., Yin, V. C., Brinkkemper, M., Capella-Pujol, J., Schriek, A. I., Torres, J. L., Bangaru, S., Burger, J. A., Poniman, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106540 · Cited by 12
“15 However, only 8 of the 17 contact residues (47”
BackgroundCui, L., Li, T., Lan, M., Zhou, M., Xue, W., Zhang, S., Wang, H., Hong, M., Zhang, Y., Yuan, L., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110208 · Cited by 13
“25,39,40 These studies underscore the rarity and uniqueness of the VH genes usage by class 5 antibodies.”
An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
Miller, N. L., Clark, T., Raman, R., & Sasisekharan, R. (2021) · Viruses · doi:10.3390/v13102009 · Cited by 10
Contributions of single-particle cryoelectron microscopy toward fighting COVID-19
Rapp, M., Shapiro, L. S., & Frank, J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.10.005 · Cited by 12
Hotspots for mutations in the SARS-CoV-2 spike glycoprotein: a correspondence analysis
Rahbar, M. R., Jahangiri, A., Khalili, S., Zarei, M., Mehrabani-Zeinabad, K., Khalesi, B., Pourzardosht, N., Hessami, A., Nezafat, N., Sadraei, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01655-y · Cited by 15
Lee, H., Knabl, L., Walter, M. F., Furth, P. A., & Hennighausen, L. G. (2022) · iScience · doi:10.1016/j.isci.2022.105369 · Cited by 12
Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Chiang, H.-L., Liang, K.-H., Lu, R., Kuo, T.-W., Lin, Y., & Wu, H. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00955-x · Cited by 13
“Moreover, IGHV3-53/66 antibodies generally share similar binding sites within the RBD [3, 13, 50] and are considered class I antibodies, which only recognize the “up” conformation of the RBD [2].”
BackgroundGuerra, D., Beaumont, T., Radić, L., Kerster, G., van der Straten, K., Yuan, M., Torres, J. L., Lee, W.-H., Liu, H., Poniman, M., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108009 · Cited by 13
“43,44 On the contrary, mAbs COVA309-22 and -38 were unable to block ACE-2 binding, suggesting that they might have different binding sites and mechanisms of action than ACE-2 blocking (Figures 2A and 2C).”
BackgroundZhu, X., Mannar, D., Srivastava, S. S., Berezuk, A., Demers, J.-P., Saville, J. W., Leopold, K., Li, W., Dimitrov, D. S., Tuttle, K. S., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.11.426269 · Cited by 12
A high-throughput, automated, cell-free expression and screening platform for antibody discoveryPreprint
Hunt, A. C., Vögeli, B., Kightlinger, W., Yoesep, D. J., Krüger, A., & Jewett, M. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.04.467378 · Cited by 12
An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters
Zhang, Y., Wu, Y., Zhang, M., Rao, H., Zhang, Z., He, X., Liang, Y., Guo, R., Yuan, Y., Sun, J., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01155-4 · Cited by 13
Liu, B., Niu, X., Deng, Y., Zhang, Z., Wang, Y., Gao, X., Liang, H., Li, Z., Wang, Q., Cheng, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114265 · Cited by 10
Li, Z., Obraztsova, A., Shang, F., Oludada, O. E., Malapit, J., Busch, K., van Straaten, M., Stebbins, C. E., Murugan, R., & Wardemann, H. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.023 · Cited by 15
Su, C., He, J., Xie, Y., Hu, Y., Li, X., Qiao, S., Liu, P., Huang, M., Zhang, R., Wang, L., et al. (2025) · hLife · doi:10.1016/j.hlife.2024.12.006 · Cited by 11
“This group of antibodies is mainly derived from IGHV3-53 and IGHV3-66, which are preferentially used to target the RBD [26,36,38,50,51] and are called “ public antibodies ” [36].”
Trends in MERS-CoV, SARS-CoV, and SARS-CoV-2 (COVID-19) Diagnosis Strategies: A Patent Review
Júnior, J. A. C. N., Santos, A. M., Oliveira, A. M. S., Guimarães, A. G., Quintans‐Júnior, L. J., Coutinho, H. D. M., Martins, N. A., Borges, L. P., & Serafini, M. R. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.563095 · Cited by 11
“For example, in RT-PCR tests the number of thermal cycles can reflect in the concentration of viral RNA, through the increase of the cycles leading to higher uncertainty in the test accuracy, due to the small viral load (33).”
BackgroundNative, engineered and de novo designed ligands targeting the SARS-CoV-2 spike protein
Costa, C., Barbosa, A. J. M., Dias, A. M. G. C., & Roque, A. C. A. (2022) · Biotechnology Advances · doi:10.1016/j.biotechadv.2022.107986 · Cited by 13
Structural insights into SARS-CoV-2 infection and therapeutics development
Sun, G., Xue, L., He, Q., Zhao, Y., Xu, W., & Wang, Z. (2021) · Stem Cell Research · doi:10.1016/j.scr.2021.102219 · Cited by 11
Characterization of a SARS-CoV-2 spike protein reference material
Stocks, B. B., Thibeault, M.-P., Schrag, J. D., & Melanson, J. E. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04000-y · Cited by 13
Hauser, B. M., Sangesland, M., Lam, E. C., Denis, K. S., Feldman, J. E., Yousif, A. S., Caradonna, T. M., Kannegieter, T., Balazs, A. B., Lingwood, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.07.415216 · Cited by 13
“Indeed, a 82 subset of spike-directed antibodies from convalescent patients can potently neutralize SARS-CoV83 2; comparable neutralizing antibodies against SARS-CoV and MERS-CoV have also been 84 identified (6, 10-15).”
BackgroundGoike, J., Hsieh, C., Horton, A. P., Gardner, E. C., Bartzoka, F., Wang, N., Javanmardi, K., Herbert, A. S., Abbasi, S. A., Renberg, R. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.07.438849 · Cited by 13
Dong, H., Zhou, R., Chen, J., Wei, J., Wei, Z., Yang, Z., Zhu, K., Yang, Y., Yang, Q., Liu, N., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012625 · Cited by 11
Public antibodies: convergent signatures in human humoral immunity against pathogens
Rao, V. N., & Coelho, C. H. (2025) · mBio · doi:10.1128/mbio.02247-24 · Cited by 12
“Hastie and colleagues identified a class of public anti-Lassa virus antibodies using IGHV3-21 paired with IGKV3-20 or IGLV2-14 .”
InfluentialCOVID-19 antibody development fueled by HIV-1 broadly neutralizing antibody research
Mendoza, P., Lorenzi, J. C. C., & Gaebler, C. (2020) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000657 · Cited by 10
No substantial preexisting B cell immunity against SARS-CoV-2 in healthy adults
Ercanoglu, M. S., Gieselmann, L., Dähling, S., Poopalasingam, N., Detmer, S., Koch, M., Korenkov, M., Halwe, S., Klüver, M., Cristanziano, V. D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103951 · Cited by 10
“, Halloran, M.E., Mercado, J.C., Kuan, G., Gordon, A., Balmaseda, 749 A., and Harris, E. (2017). Antibody-dependent enhancement of severe dengue disease in 750 humans.”
InfluentialVerkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042172 · Cited by 10
Wang, M., Fan, Q., Zhou, B., Ye, H., Shen, S., Yu, J., Cheng, L., Ge, X., Ju, B., & Zhang, Z. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111335 · Cited by 9
“The identified hotspot residue that potentially mAb against WT SARS-CoV-2 is presented as IC50 value. een P2C-1F11 and two IGHV3-53/3-66 public antibodies (P22A-1D1 and P5A- HV3-66, except for an I12V substitution within the frame region 1 (FR1), so they Yuan et al., 2020; Zhang et al., 2021).”
BackgroundHastie, K. M., Yu, X., Ana‐Sosa‐Batiz, F., Zyla, D. S., Harkins, S., Hariharan, C., Wasserman, H., Zandonatti, M. A., Miller, R., Maule, E., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112421 · Cited by 9
“Two mAbs (2A10 and 4H4) are derived from the 3–53 heavy-chain germline, which has been identified as a public clonotype for SARS-CoV-2 neutralization.(26,27)”
Sulbarán, G., Maisonnasse, P., Amen, A., Effantin, G., Guilligay, D., Dereuddre‐Bosquet, N., Burger, J. A., Poniman, M., Grobben, M., Buisson, M., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100528 · Cited by 13
Chen, Y., Prévost, J., Ullah, I., Romero, H., Lisi, V., Tolbert, W. D., Grover, J. R., Ding, S., Gong, S. Y., Beaudoin-Bussières, G., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105783 · Cited by 9
“’’(4) They are featured by relatively short heavy chain Complementary Determining Region 3s (CDRH3s), a low level of somatic mutation, as well as a similar epitope footprint and angle of approach to the RBD that directly overlaps the ACE2 footprint.(3,4) This disproportionate convergence of certain variable genes in r…”
BackgroundInfluentialBut does it work? Improving evaluations of sexuality education.
Haffner, D. W., & Goldfarb, E. S. (1997) · PubMed · Cited by 15
Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variantsPreprint
Cho, H., Gonzales-Wartz, K. K., Huang, D.-L., Yuan, M., Peterson, M., Liang, J. Y., Beutler, N., Torres, J., Cong, Y., Postnikova, E., et al. (2021) · bioRxiv · doi:10.1101/2021.04.01.437942 · Cited by 10
Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
(2023) · doi:10.1016/j.str.2023.04.010 · Cited by 11
“6,14 These antibodies are primarily encoded by near germline sequences and are commonly found in populations residing in distinct geographical regions.”
InfluentialEngineering an Antibody V Gene-Selective Vaccine
Ronsard, L., Yousif, A. S., Peabody, J., Okonkwo, V., Devant, P., Mogus, A. T., Barnes, R. M., Rohrer, D., Lönberg, N., Peabody, D. S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730471 · Cited by 10
Soluble ACE2 correlates with severe COVID-19 and can impair antibody responses
Lebedin, M. Y., Ratswohl, C., Garg, A. K., Schips, M., García, C. V., Spatt, L., Thibeault, C., Obermayer, B., Weiner, J. M., Velásquez, I. M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109330 · Cited by 9
Rodríguez‐Ubreva, J., Calafell-Segura, J., Calvillo, C. L., Keller, B., Ciudad, L., Handfield, L., de la Calle‐Fabregat, C., Godoy‐Tena, G., Andrés‐León, E., Hoo, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54732-x · Cited by 15
“…of B cells expressing the IGHV3-53 gene, which has been described as the most frequently used IGHV gene among SARS-CoV-2 neutralizing antibodies 49,50 , was higher in COVID-19 non-CVID individuals than in COVID-19 CVID patients at both progression and convalescence stages (Supplementary Fig.”
Schendel, S. L., Yu, X., Halfmann, P., Mahita, J., Ha, B., Hastie, K. M., Li, H., Bedinger, D., Troup, C. B., Li, K., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115499 · Cited by 10
“This result is consistent with the reported antibody germlines (Table S2) in that a high percentage of antibodies with the VH3-53 germline, which is predicted to contribute to high ACE-2 blocking activity, 16,17 were categorized as RBD-2 (24/27; 88%).”
Lai, C., Liu, X., Yan, Q., Lv, H., Zhou, L., Hu, L., Cai, Y., Wang, G., Chen, Y., Chai, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.664619 · Cited by 9
“Particularly, IGHV3-53, the most frequently used IGHV gene for targeting the receptor-binding domain (RBD) of the spike protein (28), was lowly expressed in the RP patient.”
BackgroundJaishwal, P., Jha, K., & Singh, S. P. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134012 · Cited by 12
Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies
Beshnova, D., Fang, Y., Du, M., Sun, Y., Du, F., Ye, J., Chen, Z. J., & Li, B. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.04.038 · Cited by 9
Discovery of Natural Lead Compound from Dendrobium sp. against SARS-CoV-2 Infection
Jiaranaikulwanitch, J., Yooin, W., Chutiwitoonchai, N., Thitikornpong, W., Sritularak, B., Rojsitthisak, P., & Vajragupta, O. (2022) · Pharmaceuticals · doi:10.3390/ph15050620 · Cited by 9
Structural basis of Omicron immune evasion: A comparative computational study
Contractor, D., Globisch, C., Swaroop, S., & Jain, A. K. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105758 · Cited by 11
“1 [36] (PDB ID: 6XC2) binding the receptor binding site region, the REGN10987 [37] (PDB ID: 6XDG) and S309 [38] (PDB ID: 6WPS) attaching at the proteoglycan site [50] and the ones binding the CR3022 [34] site (PDB ID: 6ZLR).”
Chang, T.-Y., Li, C.-J., Chao, T., Chang, S., & Chang, S. (2024) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-024-13331-y · Cited by 9
“Furthermore, it has been found that many SARS-CoV-2 neutralizing antibodies target the conserved neutralizing epitopes in the spike (S) protein, particularly in the S1-RBD and S2 regions (Li and Chang 2023; Yuan et al. 2020).”
BackgroundRetrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive
Kirby, M. B., Petersen, B. M., Faris, J. G., Kells, S. P., Sprenger, K. G., & Whitehead, T. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2412787122 · Cited by 9
“Hundreds of labs across the world began to evaluate the antibody responses to SARS - CoV - 2 natural infection and vaccination and found reproducible public class antibody responses to the Wuhan - hu - 1 strain ( 9 , 10 , 24 ).”
Castro, R., Navelsaker, S., Collet, B., Jouneau, L., Bochet, P., Quillet, E., Evensen, Ø., Sunyer, J. O., Fillatreau, S., Bruhns, P., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100149 · Cited by 8
CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
Onodera, T., Sax, N., Sato, T., Adachi, Y., Kotaki, R., Inoue, T., Shinnakasu, R., Nakagawa, T., Fukushi, S., Terooatea, T. W., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf0661 · Cited by 8
“The neutralizing activities and somatic hypermutations of RBD-binding antibodies do not correlate well each other, probably reflecting the heterogenicity of the RBD epitopes ( 8 , 14 , 27 ).”
Hsiao, Y.-C., Wallweber, H. A., Alberstein, R. G., Lin, Z., Du, C., Etxeberría, A., Aung, T., Shang, Y., Seshasayee, D., Seeger, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52442-y · Cited by 9
Zhu, X., Yu, F., Wu, Y., & Ying, T. (2021) · Antibody Therapeutics · doi:10.1093/abt/tbab008 · Cited by 10
“In parallel, as noted above, IGHV3-53 is the most frequently used IGHV gene among 294 SARSCoV-2 RBD-targeting antibodies, among them many carry limited somatic mutations [65].”
BackgroundMethodTreewattanawong, W., Sitthiyotha, T., & Chunsrivirot, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-00684-x · Cited by 8
Antibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants
Li, L., Gao, M., Jiao, P., Zu, S., Deng, Y., Wan, D., Cao, Y., Duan, J., Aliyari, S. R., Li, J., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00794-7 · Cited by 8
“3 and B38 also contained the same IGHV3-53 segment paired with either IGKV3-20, IGKV1-9 or IGLV3-21 segments, suggesting these heavy and light chain segments are frequently used in COVID19 patients in response to SARS-CoV-2 infection [3, 34, 35].”
BackgroundSARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode
Goike, J., Hsieh, C., Horton, A. P., Gardner, E. C., Zhou, L., Bartzoka, F., Wang, N., Javanmardi, K., Herbert, A. S., Abbasi, S. A., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-05649-6 · Cited by 10
Kim, S. I., Noh, J., Kim, S., Choi, Y. G., Yoo, D. K., Lee, Y., Lee, H., Jung, J., Kang, C. K., Song, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.26.174557 · Cited by 8
The Potential for SARS-CoV-2 to Evade Both Natural and Vaccine-induced ImmunityPreprint
Shang, E., & Axelsen, P. H. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.13.422567 · Cited by 9
A large-scale systematic survey of SARS-CoV-2 antibodies reveals recurring molecular featuresPreprint
Wang, Y., Yuan, M., Peng, J., Wilson, I. A., & Wu, N. C. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.26.470157 · Cited by 8
“used in RBD antibodies [28], was also enriched among antibodies in several other major CDR H3 131 clusters (e.”
Ruiz, F., Foreman, W. B., Lilly, M., Baharani, V. A., Depierreux, D. M., Chohan, V., Taylor, A. L., Guenthoer, J., Ralph, D., Matsen IV, F. A., et al. (2024) · PLOS Pathogens · doi:10.1371/journal.ppat.1012650 · Cited by 7
Metadata
- Authors
- Yuan, M., Liu, H., Wu, N. C., Lee, C.-C. D., Zhu, X., Zhao, F., Huang, D., Yu, W., Hua, Y., Tien, H., Rogers, T. F., Landais, E., Sok, D., Jardine, J. G., Burton, D. R., & Wilson, I. A.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Wilson, Ian A.
- ORCID
- Venue
- Science
- Published
- 2020-08-28
- Volume
- 369
- Issue
- 6507
- Pages
- 1119-1123
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7402627
- OpenAlex
- W3041564586
- Cited by
- 589
- References
- 53
- Citations by year
- 2026: 33 · 2025: 48 · 2024: 55 · 2023: 64 · 2022: 133 · 2021: 203 · 2020: 51
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
- PubMed Central (submittedVersion, cc-by)
- Funders
- National Institutes of Health (K99 AI139445, UM1 AI44462)
- Bill and Melinda Gates Foundation (OPP1170236)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- SARS-CoV-2, neutralizing antibodies, receptor binding domain, spike protein, ACE2 binding site, co-crystal structure, germline antibodies, affinity maturation, vaccine design, antibody structure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.